NASDAQ:NEO - NeoGenomics Stock Price, Price Target & More

$9.49 +0.03 (+0.32 %)
(As of 04/26/2018 11:00 AM ET)
Previous Close$9.46
Today's Range$9.42 - $9.55
52-Week Range$7.08 - $11.63
Volume64,297 shs
Average Volume358,280 shs
Market Capitalization$756.54 million
P/E Ratio157.67
Dividend YieldN/A
Beta0.42

About NeoGenomics (NASDAQ:NEO)

NeoGenomics logoNeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Receive NEO News and Ratings via Email

Sign-up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Testing laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NEO
CUSIPN/A
Phone239-768-0600

Debt

Debt-to-Equity Ratio0.56%
Current Ratio2.42%
Quick Ratio2.21%

Price-To-Earnings

Trailing P/E Ratio157.67
Forward P/E Ratio94.90
P/E Growth4.86

Sales & Book Value

Annual Sales$258.61 million
Price / Sales2.96
Cash Flow$0.4825 per share
Price / Cash19.67
Book Value$2.15 per share
Price / Book4.41

Profitability

EPS (Most Recent Fiscal Year)$0.06
Net Income$-840,000.00
Net Margins-1.37%
Return on Equity4.34%
Return on Assets2.15%

Miscellaneous

Employees1,030
Outstanding Shares80,570,000

How to Become a New Pot Stock Millionaire

NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

How were NeoGenomics' earnings last quarter?

NeoGenomics (NASDAQ:NEO) posted its earnings results on Wednesday, February, 21st. The medical research company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. The medical research company earned $67.79 million during the quarter, compared to the consensus estimate of $66.32 million. NeoGenomics had a negative net margin of 1.37% and a positive return on equity of 4.34%. The firm's quarterly revenue was up 12.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.05 earnings per share. View NeoGenomics' Earnings History.

When is NeoGenomics' next earnings date?

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for NeoGenomics.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics issued an update on its FY18 earnings guidance on Wednesday, February, 21st. The company provided earnings per share guidance of $0.15-0.20 for the period, compared to the Thomson Reuters consensus estimate of $0.21.

What price target have analysts set for NEO?

7 brokerages have issued 12 month target prices for NeoGenomics' stock. Their predictions range from $9.00 to $24.00. On average, they anticipate NeoGenomics' stock price to reach $17.2857 in the next year. View Analyst Ratings for NeoGenomics.

Who are some of NeoGenomics' key competitors?

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the folowing people:
  • Mr. Douglas M. VanOort, Chairman & CEO (Age 63)
  • Mr. Steven C. Jones, Exec. VP, Chief Compliance Officer & Director (Age 55)
  • Dr. Maher Albitar, Sr. VP, Chief Medical Officer and Director of R&D (Age 63)
  • Dr. Steven G. Brodie, VP of Operations & Pres of Pharma Services Division (Age 57)
  • Mr. George A. Cardoza, Pres of Pharma Services Division (Age 56)

Has NeoGenomics been receiving favorable news coverage?

Media stories about NEO stock have trended positive recently, according to Accern Sentiment Analysis. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. NeoGenomics earned a coverage optimism score of 0.39 on Accern's scale. They also gave media headlines about the medical research company an impact score of 47.17 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of NeoGenomics?

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $9.49.

How big of a company is NeoGenomics?

NeoGenomics has a market capitalization of $756.54 million and generates $258.61 million in revenue each year. The medical research company earns $-840,000.00 in net income (profit) each year or $0.06 on an earnings per share basis. NeoGenomics employs 1,030 workers across the globe.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]


MarketBeat Community Rating for NeoGenomics (NEO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  223 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  368
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe NEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NeoGenomics (NASDAQ:NEO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for NeoGenomics in the last 12 months. Their average twelve-month price target is $17.2857, suggesting that the stock has a possible upside of 82.15%. The high price target for NEO is $24.00 and the low price target for NEO is $9.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.862.712.712.40
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.2857$17.2857$15.8333$10.3333
Price Target Upside: 82.15% upside102.88% upside81.57% upside28.84% upside

NeoGenomics (NASDAQ:NEO) Consensus Price Target History

Price Target History for NeoGenomics (NASDAQ:NEO)

NeoGenomics (NASDAQ:NEO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2018BTIG ResearchUpgradeNeutral -> OutperformHighView Rating Details
3/13/2018Canaccord GenuityBoost Price Target$23.00 -> $24.00MediumView Rating Details
3/13/2018Royal Bank of CanadaBoost Price TargetOutperform$23.00 -> $24.00MediumView Rating Details
3/13/2018ScotiabankBoost Price TargetOutperform$22.00 -> $23.00MediumView Rating Details
1/3/2018CIBCSet Price TargetNeutral$19.00LowView Rating Details
10/26/2017Janney Montgomery ScottReiterated RatingBuyN/AView Rating Details
8/24/2017GabelliInitiated CoverageBuy$9.00HighView Rating Details
5/27/2017Cantor FitzgeraldSet Price TargetBuy$11.00N/AView Rating Details
11/16/2016Axiom SecuritiesReiterated RatingHold -> SellN/AView Rating Details
10/3/2016First AnalysisInitiated CoverageOverweight$11.00N/AView Rating Details
9/8/2016Raymond JamesInitiated CoverageOutperform$10.00N/AView Rating Details
7/27/2016BenchmarkBoost Price TargetBuy$10.00 -> $12.00N/AView Rating Details
7/9/2016Craig HallumReiterated RatingBuyN/AView Rating Details
5/11/2016Roth CapitalInitiated CoverageBuy$10.00N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

NeoGenomics (NASDAQ:NEO) Earnings History and Estimates Chart

Earnings by Quarter for NeoGenomics (NASDAQ:NEO)

NeoGenomics (NASDAQ:NEO) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20181$0.02$0.02$0.02
Q4 20182$0.02$0.04$0.03

NeoGenomics (NASDAQ NEO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018$0.03N/AView Earnings Details
2/21/2018Q4 2017$0.02$0.04$66.32 million$67.79 millionViewListenView Earnings Details
10/25/2017Q3 2017$0.01$0.01$63.11 million$63.05 millionViewN/AView Earnings Details
7/25/2017Q2 2017$0.01$0.04$62.95 million$66.09 millionViewN/AView Earnings Details
4/26/2017Q1 2017$0.01$0.03$61.26 million$61.68 millionViewN/AView Earnings Details
2/22/2017Q416$0.03$0.05$61.83 million$60.50 millionViewListenView Earnings Details
10/26/2016Q316$0.03$0.04$61.00 million$60.76 millionViewListenView Earnings Details
7/26/2016Q216$0.03$0.04$61.07 million$63.10 millionViewListenView Earnings Details
4/27/2016Q116($0.07)$0.03$57.00 million$59.70 millionViewListenView Earnings Details
3/1/2016Q415$0.02($0.03)$26.46 million$27.30 millionViewN/AView Earnings Details
4/28/2015Q115($0.02)($0.01)$23.36 million$23.00 millionViewN/AView Earnings Details
2/24/2015Q414$0.01$0.02$24.30 million$25.00 millionViewN/AView Earnings Details
10/30/2014Q314($0.01)$0.01$22.43 million$23.20 millionViewN/AView Earnings Details
7/17/2014Q214$0.01$0.01$19.84 million$20.70 millionViewN/AView Earnings Details
2/19/2014Q413$0.02$0.04$17.80 million$18.30 millionViewN/AView Earnings Details
10/23/2013Q313$0.01$0.02$16.84 million$16.90 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.01$16.20 million$15.60 millionViewN/AView Earnings Details
10/31/2012Q3 2012($0.01)($0.02)ViewN/AView Earnings Details
7/19/2012Q2 2012$0.01$0.01ViewN/AView Earnings Details
4/25/2012Q1 2012$0.01$0.01ViewN/AView Earnings Details
7/20/2011Q2 2011($0.01)($0.01)ViewN/AView Earnings Details
4/21/2011Q1 2011($0.01)($0.02)ViewN/AView Earnings Details
2/10/2011Q4 2010($0.02)($0.01)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.01)($0.03)ViewN/AView Earnings Details
7/29/2010Q2 2010($0.03)($0.03)ViewN/AView Earnings Details
4/29/2010Q1 2010($0.02)($0.02)ViewN/AView Earnings Details
2/25/2010Q4 2009($0.04)($0.03)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.01)($0.02)ViewN/AView Earnings Details
3/5/2009Q4 2008$0.01($0.02)ViewN/AView Earnings Details
11/6/2008Q3 2008$0.01($0.01)ViewN/AView Earnings Details
5/7/2008Q1 2008($0.01)($0.01)ViewN/AView Earnings Details
3/18/2008Q4 2007($0.01)($0.03)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

NeoGenomics (NASDAQ:NEO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

NeoGenomics (NASDAQ NEO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.20%
Institutional Ownership Percentage: 84.24%
Insider Trading History for NeoGenomics (NASDAQ:NEO)
Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

NeoGenomics (NASDAQ NEO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/27/2017Alison L HannahDirectorBuy20,000$9.19$183,800.0038,782View SEC Filing  
6/22/2017Jennifer BallietVPSell10,723$8.49$91,038.27View SEC Filing  
6/5/2017Steven A RossInsiderSell70,833$7.76$549,664.084,500View SEC Filing  
5/26/2017Jennifer BallietVPSell3,334$7.50$25,005.0010,049View SEC Filing  
3/20/2017Steven G BrodieInsiderSell50,000$7.93$396,500.0049,403View SEC Filing  
9/23/2016Maher AlbitarInsiderSell2,800$8.40$23,520.00View SEC Filing  
9/20/2016Maher AlbitarInsiderSell105,300$8.20$863,460.00105,300View SEC Filing  
9/12/2016Maher AlbitarInsiderSell60,075$8.23$494,417.25165,375View SEC Filing  
8/19/2016Maher AlbitarInsiderSell370,000$8.23$3,045,100.00263,492View SEC Filing  
5/27/2016Oort Douglas M VanCEOSell481,387$8.73$4,202,508.511,675,000View SEC Filing  
5/18/2016Steven A RossInsiderSell18,000$8.50$153,000.004,500View SEC Filing  
5/9/2016Steven A RossInsiderSell15,000$8.22$123,300.004,500View SEC Filing  
5/2/2016Steven C JonesVPSell177,745$8.21$1,459,286.45266,251View SEC Filing  
4/29/2016Steven A RossInsiderSell112,500$8.11$912,375.00117,000View SEC Filing  
3/11/2016George CardozaCFOSell32,000$6.83$218,560.00221,089View SEC Filing  
3/9/2016Oort Douglas M VanCEOSell450,000$7.10$3,195,000.002,125,000View SEC Filing  
3/3/2016Alison L HannahDirectorBuy10,000$6.90$69,000.0011,560View SEC Filing  
12/7/2015Lynn A TetraultDirectorBuy3,500$7.72$27,020.005,060View SEC Filing  
12/3/2015Robert J ShovlinCOOBuy6,550$7.75$50,762.506,550View SEC Filing  
11/27/2015Steven C JonesVPSell385,000$8.09$3,114,650.00286,251View SEC Filing  
11/2/2015Bruce K CrowtherDirectorBuy6,400$7.81$49,984.00View SEC Filing  
12/19/2014Robert H HorelVPSell32,389$4.21$136,357.69View SEC Filing  
12/18/2014Robert H HorelVPSell62,893$4.20$264,150.60View SEC Filing  
12/4/2014Michael T DentDirectorSell11,800$4.50$53,100.00View SEC Filing  
11/26/2014George CardozaCFOSell60,000$4.28$256,800.00View SEC Filing  
11/21/2014Michael T DentDirectorSell33,200$4.51$149,732.00View SEC Filing  
5/22/2014Robert P GaspariniInsiderSell100,000$3.49$349,000.00View SEC Filing  
5/19/2014Robert GaspariniInsiderSell10,000$3.65$36,500.008,439View SEC Filing  
3/28/2014Maher AlbitarInsiderBuy14,492$3.51$50,866.92View SEC Filing  
3/5/2014Michael T DentDirectorSell300,000$3.00$900,000.00View SEC Filing  
12/11/2013Robert P GaspariniInsiderSell20,100$3.70$74,370.00View SEC Filing  
12/9/2013George CardozaCFOSell20,000$3.66$73,200.00View SEC Filing  
12/5/2013Robert P GaspariniInsiderSell32,996$3.67$121,095.32View SEC Filing  
12/3/2013Robert P GaspariniInsiderSell32,146$3.67$117,975.82View SEC Filing  
11/25/2013Steven C JonesVPSell112,969$3.58$404,429.02View SEC Filing  
4/30/2013Steven C JonesDirectorSell100,000$3.71$371,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

NeoGenomics (NASDAQ NEO) News Headlines

Source:
DateHeadline
NeoGenomics (NEO) & Intertek (IKTSY) Financial ContrastNeoGenomics (NEO) & Intertek (IKTSY) Financial Contrast
www.americanbankingnews.com - April 25 at 9:26 PM
 Brokerages Expect NeoGenomics (NEO) to Post $0.03 EPS Brokerages Expect NeoGenomics (NEO) to Post $0.03 EPS
www.americanbankingnews.com - April 25 at 11:28 AM
Equities Analysts Offer Predictions for NeoGenomics Q4 2018 Earnings (NEO)Equities Analysts Offer Predictions for NeoGenomics' Q4 2018 Earnings (NEO)
www.americanbankingnews.com - April 25 at 9:49 AM
NeoGenomics (NEO) Scheduled to Post Quarterly Earnings on TuesdayNeoGenomics (NEO) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 24 at 6:52 AM
NeoGenomics (NEO) versus Intertek Group (IKTSY) Critical AnalysisNeoGenomics (NEO) versus Intertek Group (IKTSY) Critical Analysis
www.americanbankingnews.com - April 18 at 1:34 PM
NeoGenomics (NEO) Upgraded by BidaskClub to BuyNeoGenomics (NEO) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - April 18 at 9:51 AM
NeoGenomics (NEO) Upgraded at BidaskClubNeoGenomics (NEO) Upgraded at BidaskClub
www.americanbankingnews.com - April 17 at 1:54 PM
NeoGenomics (NEO) Upgraded by ValuEngine to BuyNeoGenomics (NEO) Upgraded by ValuEngine to Buy
www.americanbankingnews.com - April 17 at 10:29 AM
BTIG Upgrades Neogenomics (NEO) to BuyBTIG Upgrades Neogenomics (NEO) to Buy
www.streetinsider.com - April 16 at 8:46 AM
NeoGenomics (NEO) Rating Increased to Buy at BTIG ResearchNeoGenomics (NEO) Rating Increased to Buy at BTIG Research
www.americanbankingnews.com - April 16 at 7:39 AM
NeoGenomics, Inc. (NEO) Receives Average Rating of "Hold" from BrokeragesNeoGenomics, Inc. (NEO) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 11 at 7:35 PM
Contrasting Intertek Group (IKTSY) and NeoGenomics (NEO)Contrasting Intertek Group (IKTSY) and NeoGenomics (NEO)
www.americanbankingnews.com - April 10 at 9:21 AM
 Analysts Anticipate NeoGenomics, Inc. (NEO) Will Post Quarterly Sales of $64.04 Million Analysts Anticipate NeoGenomics, Inc. (NEO) Will Post Quarterly Sales of $64.04 Million
www.americanbankingnews.com - April 10 at 3:30 AM
 Analysts Anticipate NeoGenomics, Inc. (NEO) to Post $0.03 EPS Analysts Anticipate NeoGenomics, Inc. (NEO) to Post $0.03 EPS
www.americanbankingnews.com - April 8 at 1:22 PM
NeoGenomics (NEO) Cut to "Buy" at BidaskClubNeoGenomics (NEO) Cut to "Buy" at BidaskClub
www.americanbankingnews.com - April 6 at 7:03 PM
NeoGenomics (NEO) Upgraded to "Hold" by Zacks Investment ResearchNeoGenomics (NEO) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 4 at 11:26 PM
Head to Head Review: NeoGenomics (NEO) & Intertek Group (IKTSY)Head to Head Review: NeoGenomics (NEO) & Intertek Group (IKTSY)
www.americanbankingnews.com - April 3 at 11:39 PM
NeoGenomics Schedules its First Quarter Earnings Release for May 1, 2018NeoGenomics Schedules its First Quarter Earnings Release for May 1, 2018
feeds.benzinga.com - April 2 at 5:46 PM
Analyzing Intertek Group (IKTSY) & NeoGenomics (NEO)Analyzing Intertek Group (IKTSY) & NeoGenomics (NEO)
www.americanbankingnews.com - April 2 at 9:14 AM
NeoGenomics (NEO) versus Intertek Group (IKTSY) Head to Head ComparisonNeoGenomics (NEO) versus Intertek Group (IKTSY) Head to Head Comparison
www.americanbankingnews.com - April 2 at 1:32 AM
Reviewing NeoGenomics (NEO) and Its RivalsReviewing NeoGenomics (NEO) and Its Rivals
www.americanbankingnews.com - March 28 at 5:28 PM
NeoGenomics (NEO) Rating Lowered to Sell at BidaskClubNeoGenomics (NEO) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - March 27 at 3:28 PM
NeoGenomics (NEO) Stock Rating Upgraded by BidaskClubNeoGenomics (NEO) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 25 at 2:34 PM
NeoGenomics (NEO) Lifted to Hold at Zacks Investment ResearchNeoGenomics (NEO) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - March 24 at 3:56 PM
 Analysts Expect NeoGenomics, Inc. (NEO) Will Post Quarterly Sales of $64.04 Million Analysts Expect NeoGenomics, Inc. (NEO) Will Post Quarterly Sales of $64.04 Million
www.americanbankingnews.com - March 24 at 7:54 AM
NeoGenomics, Inc. (NEO) Expected to Post Earnings of $0.03 Per ShareNeoGenomics, Inc. (NEO) Expected to Post Earnings of $0.03 Per Share
www.americanbankingnews.com - March 22 at 1:28 PM
Global Cancer/Tumor Profiling Market Report 2017 Analysis & Forecasts 2013-2023 - Rising Utility of Biomarkers in ... - PR Newswire (press release)Global Cancer/Tumor Profiling Market Report 2017 Analysis & Forecasts 2013-2023 - Rising Utility of Biomarkers in ... - PR Newswire (press release)
www.prnewswire.com - March 20 at 4:51 PM
NeoGenomics Announces Executive AppointmentsNeoGenomics Announces Executive Appointments
finance.yahoo.com - March 20 at 9:03 AM
Research Report Identifies Chatham Lodging Trust (REIT), Independent Bank Group, NeoGenomics, Black Knight, Aethlon Medical, and PRA Group with Renewed Outlook — Fundamental Analysis, Calculating Forward MovementResearch Report Identifies Chatham Lodging Trust (REIT), Independent Bank Group, NeoGenomics, Black Knight, Aethlon Medical, and PRA Group with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
finance.yahoo.com - March 19 at 8:58 AM
NeoGenomics, Inc. (NEO) Given Average Recommendation of "Hold" by BrokeragesNeoGenomics, Inc. (NEO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 17 at 7:38 PM
NeoGenomics (NEO) Given New $24.00 Price Target at Canaccord GenuityNeoGenomics (NEO) Given New $24.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - March 13 at 5:17 PM
Scotiabank Increases NeoGenomics (NEO) Price Target to $23.00Scotiabank Increases NeoGenomics (NEO) Price Target to $23.00
www.americanbankingnews.com - March 13 at 5:16 PM
NeoGenomics (NEO) Given New $24.00 Price Target at Royal Bank of CanadaNeoGenomics (NEO) Given New $24.00 Price Target at Royal Bank of Canada
www.americanbankingnews.com - March 13 at 5:16 PM
NeoGenomics (NEO) Lowered to "Sell" at ValuEngineNeoGenomics (NEO) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - March 11 at 11:42 PM
NeoGenomics, Inc. (NEO) Expected to Announce Quarterly Sales of $64.04 MillionNeoGenomics, Inc. (NEO) Expected to Announce Quarterly Sales of $64.04 Million
www.americanbankingnews.com - March 7 at 4:27 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating NeoGenomics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating NeoGenomics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
www.prnewswire.com - March 7 at 7:49 AM
NeoGenomics, Inc. (NEO) Shares Bought by Ranger Investment Management L.P.NeoGenomics, Inc. (NEO) Shares Bought by Ranger Investment Management L.P.
www.americanbankingnews.com - March 6 at 2:10 PM
Next Century Growth Investors LLC Sells 905,209 Shares of NeoGenomics, Inc. (NEO)Next Century Growth Investors LLC Sells 905,209 Shares of NeoGenomics, Inc. (NEO)
www.americanbankingnews.com - March 2 at 5:58 PM
Form 4 NEOGENOMICS INC For: Feb 26 Filed by: SHOVLIN ROBERT J. - StreetInsider.comForm 4 NEOGENOMICS INC For: Feb 26 Filed by: SHOVLIN ROBERT J. - StreetInsider.com
www.streetinsider.com - March 2 at 5:40 PM
NeoGenomics, Inc. (NEO) Shares Sold by Hudson Bay Capital Management LPNeoGenomics, Inc. (NEO) Shares Sold by Hudson Bay Capital Management LP
www.americanbankingnews.com - March 2 at 1:32 PM
NeoGenomics, Inc. (NEO) Holdings Cut by Cortina Asset Management LLCNeoGenomics, Inc. (NEO) Holdings Cut by Cortina Asset Management LLC
www.americanbankingnews.com - March 1 at 11:53 AM
Royce & Associates LP Sells 60,000 Shares of NeoGenomics, Inc. (NEO)Royce & Associates LP Sells 60,000 Shares of NeoGenomics, Inc. (NEO)
www.americanbankingnews.com - February 28 at 9:34 AM
NeoGenomics (NEO) Raised to "Hold" at Zacks Investment ResearchNeoGenomics (NEO) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 23 at 10:06 AM
NeoGenomics (NEO) Announces  Earnings ResultsNeoGenomics (NEO) Announces Earnings Results
www.americanbankingnews.com - February 21 at 9:21 AM
NeoGenomics (NEO) Releases FY18 Earnings GuidanceNeoGenomics (NEO) Releases FY18 Earnings Guidance
www.americanbankingnews.com - February 21 at 9:08 AM
NeoGenomics, Inc. (NEO)NeoGenomics, Inc. (NEO)
finance.yahoo.com - February 21 at 8:52 AM
NeoGenomics Reports Revenue of $67.8 Million on 18.7% Clinical Volume Growth and $10.5 Million of Adjusted EBITDA in the Fourth Quarter of 2017NeoGenomics Reports Revenue of $67.8 Million on 18.7% Clinical Volume Growth and $10.5 Million of Adjusted EBITDA in the Fourth Quarter of 2017
finance.yahoo.com - February 21 at 8:52 AM
NeoGenomics beats Street 4Q forecastsNeoGenomics beats Street 4Q forecasts
finance.yahoo.com - February 21 at 8:52 AM
NeoGenomics, Inc. (NEO) Given Consensus Recommendation of "Buy" by BrokeragesNeoGenomics, Inc. (NEO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 20 at 7:44 PM
Zacks: Brokerages Anticipate NeoGenomics, Inc. (NEO) Will Announce Quarterly Sales of $65.83 MillionZacks: Brokerages Anticipate NeoGenomics, Inc. (NEO) Will Announce Quarterly Sales of $65.83 Million
www.americanbankingnews.com - February 18 at 2:38 AM

SEC Filings

NeoGenomics (NASDAQ:NEO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

NeoGenomics (NASDAQ:NEO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

NeoGenomics (NASDAQ NEO) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.